Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG
82b and 82c randomised trials.
(7) The incidence of the most severe adverse events, systemic or disseminated BCG (dBCG), is estimated at 992 per 100 000 HIV-infected infants, typically occurring at a median age of 7-8 months and with an all-cause mortality of approximately 75%.8 Confirmed BCG dissemination has only been documented in infants with rapid HIV disease progression in the first year of life.
(12,13) This revision was primarily based on the documented risk of dBCG disease in HIV-infected infants and not on the risk of local and regional BCG adverse events.
(17) Infants whose HAART was delayed until clinically or immunologically indicated had an incidence of BCG IRIS of 15.7%; early HAART reduced the risk 3-fold to 5.2%.18 To date, most infants diagnosed with dBCG disease were not on HAART or were started on HAART shortly before presentation.
Tissue microarrays compared with whole sections and biochemical analyses: a subgroup analysis of DBCG
The Danish Breast Cancer Cooperative Group (DBCG) also found that HER2 overexpression (found in 33% of 805 patients) was not predictive of response to either CEF or CMF .
The value of TOP2A gene copy number variation as a biomarker in breast cancer: update of DBCG trial 89D.
The four studies in this analysis are the Belgian three-arm trial, the Canadian National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial, the Danish Breast Cancer Cooperative Group (DBCG
) trial and the UK National Epirubicin Adjuvant Trial (NEAT) study.